SyntheMed plans 2006 launch for cardiac surgery adhesion barrier:
This article was originally published in Clinica
Executive Summary
SyntheMed, formerly Life Medical Sciences, says it has enrolled the first patient in a multicentre European trial testing its REPEL-CV adhesion barrier in cardiac surgery, in preparation for an anticipated 2006 EU product launch. The Oceanport, New Jersey firm is also testing the adhesion barrier in US trials designed to support a marketing application for the product. Post-operative adhesion formation can be a serious complication of open-heart surgery, the firm said, adding that REPEL-CV could become the first adhesion barrier approved by the FDA for use in cardiac surgery. The product targets an annual worldwide market opportunity estimated to be worth around $250m.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.